DE69729587D1 - Behandlung von migränekopfschmerzen mit metoclopramid und einem nsaid - Google Patents

Behandlung von migränekopfschmerzen mit metoclopramid und einem nsaid

Info

Publication number
DE69729587D1
DE69729587D1 DE69729587T DE69729587T DE69729587D1 DE 69729587 D1 DE69729587 D1 DE 69729587D1 DE 69729587 T DE69729587 T DE 69729587T DE 69729587 T DE69729587 T DE 69729587T DE 69729587 D1 DE69729587 D1 DE 69729587D1
Authority
DE
Germany
Prior art keywords
metoclopramide
nsaid
treating migraine
migraine headache
nsaids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69729587T
Other languages
English (en)
Other versions
DE69729587T2 (de
Inventor
R Plachetka
T Chowhan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pozen Inc
Original Assignee
Pozen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pozen Inc filed Critical Pozen Inc
Application granted granted Critical
Publication of DE69729587D1 publication Critical patent/DE69729587D1/de
Publication of DE69729587T2 publication Critical patent/DE69729587T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Yarns And Mechanical Finishing Of Yarns Or Ropes (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE69729587T 1996-11-12 1997-11-12 Behandlung von migränekopfschmerzen mit metoclopramid und einem nsaid Expired - Fee Related DE69729587T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US74833296A 1996-11-12 1996-11-12
US748332 1996-11-12
US966506 1997-11-10
US08/966,506 US6077539A (en) 1996-11-12 1997-11-10 Treatment of migraine headache
PCT/US1997/020611 WO1998020870A1 (en) 1996-11-12 1997-11-12 Improved treatment of migraine headache

Publications (2)

Publication Number Publication Date
DE69729587D1 true DE69729587D1 (de) 2004-07-22
DE69729587T2 DE69729587T2 (de) 2005-06-23

Family

ID=27114923

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69729587T Expired - Fee Related DE69729587T2 (de) 1996-11-12 1997-11-12 Behandlung von migränekopfschmerzen mit metoclopramid und einem nsaid

Country Status (11)

Country Link
US (3) US6077539A (de)
EP (1) EP1014961B1 (de)
JP (2) JP3759624B2 (de)
AT (1) ATE269071T1 (de)
AU (1) AU732217C (de)
CA (1) CA2269745C (de)
DE (1) DE69729587T2 (de)
DK (1) DK1014961T3 (de)
ES (1) ES2222522T3 (de)
PT (1) PT1014961E (de)
WO (1) WO1998020870A1 (de)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6586458B1 (en) 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6077539A (en) * 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
GB9814215D0 (en) * 1998-07-01 1998-09-02 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
AU759307B2 (en) 1998-11-02 2003-04-10 Merck Sharp & Dohme Corp. Method of treating migraines and pharmaceutical compositions
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
AU3596500A (en) * 1999-02-19 2000-09-04 Pozen, Inc. Formulation of 5-ht agonists with cox-2 inhibitors
AU2001285334A1 (en) 2000-08-29 2002-03-13 Peter Van Patten Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid
US6440983B1 (en) * 2000-12-21 2002-08-27 Mary Theresa Frank-Kollman Compositions and methods for relieving headache symptoms in aspirin-sensitive headache sufferers
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US20030198669A1 (en) * 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
US6685951B2 (en) 2001-07-05 2004-02-03 R. T. Alamo Ventures I, Inc. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
US20030017175A1 (en) * 2001-07-05 2003-01-23 R.T. Alamo Ventures I, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
US7838026B2 (en) 2001-09-28 2010-11-23 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
US7122143B2 (en) 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
MXPA04002980A (es) 2001-09-28 2005-06-20 Johnson & Johnson Formas de dosificacion que tienen un nucleo interior y coraza exterior con diferentes formas.
EP1519753A1 (de) * 2002-07-09 2005-04-06 B.M.R.A. Corporation B.V. Kombinationszusammensetzung von einem thromboxan-a2-rezeptor antagonist und einem cyclooxygenase-2 hemmer
US7807197B2 (en) 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
AU2003303631B2 (en) * 2002-12-26 2008-05-29 Nuvo Pharmaceuticals (Ireland) Designated Activity Company Multilayer Dosage Forms Containing NSAIDs and Triptans
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20050137265A1 (en) * 2003-03-31 2005-06-23 Haley Eugene T. Rapidly dissolving metoclopramide solid oral dosage and method thereof
US20040192781A1 (en) * 2003-03-31 2004-09-30 Haley Eugene T. Method of administration for metoclopramide and pharmaceutical formulation therefor
CA2527368A1 (en) * 2003-06-06 2004-12-23 Glaxo Group Limited Pharmaceutical composition
AU2004264722A1 (en) * 2003-08-07 2005-02-24 B.M.R.A. Corporation B.V. Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxigenase-1
EP1663159A4 (de) * 2003-09-10 2010-06-09 Map Pharmaceuticals Inc Aerosol-formulierungen zur abgabe von dihydroergotamin an den systemischen kreislauf durch pulmonale inhalation
US7879354B2 (en) 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US8067029B2 (en) 2004-01-13 2011-11-29 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US20070065486A1 (en) * 2004-05-21 2007-03-22 Migco Limited Migraine remedy
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
US20050282879A1 (en) * 2004-06-17 2005-12-22 Foad Salehani Methods and composition for treatment of migraine and symptoms thereof
US20060178349A1 (en) * 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
EP1954298A4 (de) 2005-11-28 2012-10-31 Imaginot Pty Ltd Abgabesystem für eine orale therapeutische verbindung
BRPI0708640A8 (pt) * 2006-03-06 2018-04-24 Pozen Inc composição farmacêutica, e, métodos para tratar um paciente com dor de cabeça de enxaqueca, para tratar um paciente com dor e para tratar um paciente com enxaqueca
US9265732B2 (en) 2006-03-06 2016-02-23 Pozen Inc. Dosage forms for administering combinations of drugs
WO2007144175A2 (en) * 2006-06-16 2007-12-21 Lek Pharmaceuticals D.D. Pharmaceutical composition comprising hydrochlorothiazide and telmisartan
US8128460B2 (en) * 2006-09-14 2012-03-06 The Material Works, Ltd. Method of producing rust inhibitive sheet metal through scale removal with a slurry blasting descaling cell
ITMI20062254A1 (it) * 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
KR20090129998A (ko) 2007-02-11 2009-12-17 맵 파마슈티컬스, 인코포레이티드 부작용 프로파일을 최소화하면서 편두통의 빠른 완화를 가능하게 하는 ｄｈｅ의 치료적 투여 방법
PE20090185A1 (es) 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
TR200708925A1 (tr) * 2007-12-26 2009-07-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Kontrollü salım sağlayan flurbiprofen ve kas gevşetici kombinasyonları
EP2240022B1 (de) * 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Oxycodone und Promethazine enthaltende zweischichtige Tabletten
US20090186086A1 (en) * 2008-01-17 2009-07-23 Par Pharmaceutical, Inc. Solid multilayer oral dosage forms
MX344778B (es) * 2008-01-25 2017-01-06 Duo-Ge Combinacion de medicamentos orales unidos por una envoltura.
EP2344139A1 (de) 2008-09-09 2011-07-20 AstraZeneca AB Verfahren zur abgabe einer pharmazeutischen zusammensetzung an einen patienten, der diese benötigt
US8551454B2 (en) * 2009-03-13 2013-10-08 Luitpold Pharmaceuticals, Inc. Device for intranasal administration
AU2010266026B2 (en) * 2009-06-25 2014-08-07 Nuvo Pharmaceuticals (Ireland) Designated Activity Company Method for treating a patient in need of aspirin therapy
EP2445499A4 (de) * 2009-06-25 2013-02-27 Astrazeneca Ab Verfahren zur behandlung eines patienten mit risiko der entwicklung eines nsaid-assoziierten geschwürs
WO2010151804A1 (en) * 2009-06-26 2010-12-29 Map Pharmaceuticals, Inc. Administration of dihydroergotamine mesylate particles using a metered dose inhaler
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
BR112014016085A8 (pt) 2011-12-28 2017-07-04 Pozen Inc composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
EP2702875A1 (de) * 2012-08-31 2014-03-05 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Beschichtete Nahrungsmittel mit einem Schokoladenkern und Prozessen für ihre Herstellung
PL3060203T3 (pl) * 2013-10-23 2018-01-31 Bayer Healthcare Llc Tabletka musująca zawierająca wysoki poziom aspiryny
EA201990684A1 (ru) 2013-12-24 2020-12-30 Вирджиния Коммонвелт Юниверсити Способы применения оксигенированных холестеролсульфатов (ocs)
WO2015157729A1 (en) * 2014-04-11 2015-10-15 Wilmink Michael Pharmaceutical formulations an comprising analgesic agent, a nonsteroidal anti-inflammatory agent, a gastric acid production suppressant and an anti-nauseant
EP3226972A4 (de) 2014-12-01 2018-08-08 Achelios Therapeutics, Inc. Verfahren und zusammensetzungen zur behandlung von migräne und leiden in zusammenhang mit schmerzen
US11607456B2 (en) 2015-02-10 2023-03-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729773B2 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695430B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11045549B2 (en) 2015-02-10 2021-06-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11738085B2 (en) 2015-02-10 2023-08-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10517950B1 (en) 2015-02-10 2019-12-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013806B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11602563B2 (en) 2015-02-10 2023-03-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821181B2 (en) 2015-02-10 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10058614B2 (en) 2015-02-10 2018-08-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933137B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013805B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10532101B1 (en) 2015-02-10 2020-01-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780166B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10653777B2 (en) 2015-02-10 2020-05-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10722583B2 (en) 2015-02-10 2020-07-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11110173B2 (en) 2015-02-10 2021-09-07 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US10758618B2 (en) 2015-02-10 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933136B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729774B1 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10799588B2 (en) 2015-02-10 2020-10-13 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10512692B2 (en) 2015-02-10 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695429B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10537642B1 (en) 2015-02-10 2020-01-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780165B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10702602B2 (en) 2015-02-10 2020-07-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
JP6851365B2 (ja) 2015-03-26 2021-03-31 ジャクリーン・エム・イヴァーセン 宿酔に伴う症状を抑制するための方法及び組成物
EP3423041A4 (de) 2016-03-04 2019-09-11 Charleston Laboratories, Inc. Pharmazeutische zusammensetzungen
US10729696B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821182B2 (en) 2017-06-29 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10905693B2 (en) 2017-01-04 2021-02-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10894053B2 (en) 2017-01-04 2021-01-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11471465B2 (en) 2017-01-04 2022-10-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729697B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583144B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617755B2 (en) 2017-01-04 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10561664B1 (en) 2017-01-04 2020-02-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10471014B2 (en) 2017-01-04 2019-11-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11207327B2 (en) 2017-01-04 2021-12-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433078B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
DK3565550T3 (da) 2017-01-04 2021-01-18 Axsome Therapeutics Inc Farmaceutiske sammensætninger omfattende meloxicam og rizatriptan
US11266657B2 (en) 2017-01-04 2022-03-08 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433079B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583088B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11801250B2 (en) 2017-01-04 2023-10-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11806354B2 (en) 2017-01-04 2023-11-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10940153B2 (en) 2017-01-04 2021-03-09 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10512693B2 (en) 2017-06-29 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10987358B2 (en) 2017-06-29 2021-04-27 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10688185B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617791B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11759522B2 (en) 2017-06-29 2023-09-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11219626B2 (en) 2017-06-29 2022-01-11 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11510927B2 (en) 2017-06-29 2022-11-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10688102B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Combination treatment for migraine and other pain
US11185550B2 (en) 2017-06-29 2021-11-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617756B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10918722B2 (en) 2017-06-29 2021-02-16 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11865117B2 (en) 2017-06-29 2024-01-09 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US10758617B2 (en) 2017-06-29 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
CN111295198A (zh) * 2017-11-01 2020-06-16 表飞鸣制药株式会社 特定的NSAIDs及PPI所诱发的小肠损伤的预防或治疗剂
JP2020103185A (ja) * 2018-12-27 2020-07-09 花王株式会社 密封容器入り発泡性経口錠剤
US11779541B2 (en) * 2019-03-26 2023-10-10 Johnson & Johnson Consumer Inc. Immediate release dosage form

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US423971A (en) * 1890-03-25 Implement for rotating tools
US588616A (en) * 1897-08-24 stuart
US2099402A (en) 1934-01-17 1937-11-16 Pratt Food Company Pill or tablet
IL45357A (en) * 1974-07-26 1978-04-30 Yeda Res & Dev Pharmaceutical compositions comprising aromatic amino acids as inhibitors of prostaglandin action
US4235971A (en) * 1978-06-09 1980-11-25 Dynatech Laboratories, Incorporated Inoculator
US4380540A (en) * 1978-11-14 1983-04-19 Beecham Group Limited Tablets
YU17780A (en) 1980-01-23 1984-10-31 Lek Tovarna Farmacevtskih Process for preparing a stable solution of ergot alkaloid derivatives
CA1165242A (en) 1981-07-01 1984-04-10 Hovsep Simonian Compressed and formed alkaline component suitable for use in buffered acetylsalicylic acid product
US4664915A (en) * 1981-07-01 1987-05-12 Bristol-Myers Company Compressed and formed alkaline component suitable for use in buffered aspirin product
US4888343A (en) * 1986-09-15 1989-12-19 Bristol-Myers Company Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process
US5155105A (en) * 1986-09-15 1992-10-13 Bristol-Myers Squibb Company Pharmaceutical methods for relief of dysmenorrhea and/or premenstrual syndrome and process
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US4999226A (en) 1988-06-01 1991-03-12 Merrell Dow Pharmaceuticals Inc. Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination
CA2020018A1 (en) * 1990-06-27 1991-12-28 Don L. Simmons Method and composition for treating the migraine complex
WO1993000886A1 (de) * 1991-07-01 1993-01-21 Gerhard Gergely Reaktionsdotierte brausesysteme
US5288507A (en) * 1992-07-29 1994-02-22 Merck & Co., Inc. Ibuprofen antacid combinations
US5573776A (en) * 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
IT1264696B1 (it) 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
FR2712809B1 (fr) * 1993-11-26 1996-04-12 Union Pharma Scient Appl Nouvelle composition pharmaceutique destinée à la préparation d'une poudre stable contenant, à titre d'ingrédient actif, une association d'acide acétylsalicylique et de métoclopramide.
US5470306A (en) * 1994-02-23 1995-11-28 Kirschner Medical Corporation Medical bandaging article and packaging system
TR199701092T1 (xx) 1995-04-03 1998-01-21 Chugai Seiyaku Kabushiki Kaisha Et Al Sukralfat içeren farmakotik kompozisyonlar.
FR2741532B1 (fr) * 1995-11-28 1998-08-21 Bouchara Sa Nouvelles compositions pharmaceutiques a action antimigraineuse et leur mode de preparation
US6077539A (en) * 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
US5885616A (en) 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
US6106862A (en) * 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet

Also Published As

Publication number Publication date
ES2222522T3 (es) 2005-02-01
US6479551B1 (en) 2002-11-12
EP1014961A1 (de) 2000-07-05
PT1014961E (pt) 2004-10-29
US20030040537A1 (en) 2003-02-27
AU732217B2 (en) 2001-04-12
US6077539A (en) 2000-06-20
WO1998020870A1 (en) 1998-05-22
DE69729587T2 (de) 2005-06-23
JP3759624B2 (ja) 2006-03-29
ATE269071T1 (de) 2004-07-15
DK1014961T3 (da) 2004-10-25
US7030162B2 (en) 2006-04-18
CA2269745C (en) 2003-07-29
CA2269745A1 (en) 1998-05-22
AU5201098A (en) 1998-06-03
JP2005343906A (ja) 2005-12-15
EP1014961B1 (de) 2004-06-16
AU732217C (en) 2005-09-15
JP2000507614A (ja) 2000-06-20
EP1014961A4 (de) 2001-04-11

Similar Documents

Publication Publication Date Title
DE69729587D1 (de) Behandlung von migränekopfschmerzen mit metoclopramid und einem nsaid
ATE286393T1 (de) Formulation von 5-ht agonisten
DE69805202D1 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
DE69728782D1 (de) Verwendung von no synthase hemmern und fängern von reaktiven sauerstoffsformen zur behandlung von ischämie
EA199900045A1 (ru) Производные спиропиперидина и их использование в качестве терапевтических агентов
ID29393A (id) Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah
ATE328588T1 (de) Behandlung von nicotinsucht und sucht bedingtem verhalten
EA199800772A1 (ru) Производные 6-фенилпиридил-2-амина
ATE257386T1 (de) Pharmazeutische zusammensetzungen enthaltend eine mischung von selbstvernetzter und nichtselbstvernetzter hyaluronsäure zur behandlung von arthropathien
BR0307508A (pt) Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de tratamento de doença
EA199700251A1 (ru) 5-замещенные-3-(1,2,3,6-тетрагидропиридин-4-ил)- и 3-(пиперидин-4-ил)-1н-индолы и их фармацевтически приемлемые соли и сольваты, фармацевтическая композиция на их основе, способ активации рецепторов 5-нти способ ингибирования нейронной белковой транссудации
HUT74992A (en) Use of serotonin antagonist indol derivatives for producing pharmaceutical compositions using for treating fibromyalgia
DE3650138D1 (de) Mittel zur bekämpfung des schmerzes, der depression und zur beruhigung.
MX9302011A (es) Derivados de indol.
RU94020410A (ru) Способ лечения или профилактики рвоты у млекопитающих и человека с использованием некоторых хинуклидиновых, пиперидиновых, азанорборнановых, этилендиаминовых производных и родственных им соединений
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
ATE209909T1 (de) Verwendung von tachykinin-antagonisten zur behandlung von erbrechen
DE69735482D1 (de) Spiro-azacyclische derivate, deren herstellung und verwendung als tachykinin-antagonisten
DE60118956D1 (de) Calciumkanalantagonisten vom n-typ zur behandlung von schmerzen
EA200100799A1 (ru) Антагонисты фактора опухолевого некроза и их применение при эндометриозе
SE0004054D0 (sv) N-type calcium channel antagonists for the treatment of pain
TR199901782T2 (xx) Migren tedavisi i�in ibuprofen ve domperidon ihtiva eden farmas�tik bile�imler.
EA200100098A1 (ru) Соли пароксетина
ATE548048T1 (de) Oncomodulin zur behandlung von neurologishen erkrankungen
EA199901061A1 (ru) Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee